Holen Sie sich die Stockscreener-App
610.46
0.05%
0.64
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$609.82
Offen:
$614.94
24-Stunden-Volumen:
431.66K
Relative Volume:
0.22
Marktkapitalisierung:
$225.53B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.87B
KGV:
33.56
EPS:
18.1888
Netto-Cashflow:
$6.75B
1W Leistung:
-0.59%
1M Leistung:
+3.72%
6M Leistung:
+31.39%
1J Leistung:
+27.26%
1-Tages-Spanne:
$605.65
$616.00
1-Wochen-Bereich:
$594.82
$616.00
52-Wochen-Spanne:
$435.27
$647.00
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, NTRA, IQV, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
609.95 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
201.95 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
334.89 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
266.60 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
145.66 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
About Thermo Fisher Scientific rStock - Coinbase
Thermo Fisher Scientific Inc. (TMO) latest stock news and headlines - Yahoo Finance UK
Thermo Fisher Scientific Inc. stock rises Friday, outperforms market - MarketWatch
Thermo Fisher stock gains on UBS upgrade and solid Q2 growth - ad-hoc-news.de
Thermo Fisher Scientific Share Price Today (TMO) | Live Chart, News & Stock Market - TechGraph
Thermo Fisher Drew Two Upgrades Near Its Highs. Here’s Where the Stock Could Go - TIKR.com
Thermo Fisher stock gains analyst support as UBS lifts target to 730 dollars - ad-hoc-news.de
Thermo Fisher, Wells Fargo, Nutrien And More On CNBC’s ‘Final Trades’ - Benzinga
Thermo Fisher stock heads into the open after a 0.4% loss - ad-hoc-news.de
UBS Upgrades Thermo Fisher Scientific to Buy From Neutral, Adjusts Price Target to $730 From $540 - Moomoo
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says - Yahoo Finance
UBS upgrades Thermo Fisher Scientific stock rating on growth outlook By Investing.com - Investing.com Canada
Thermo Fisher stock slips as dividend date nears - ad-hoc-news.de
Thermo Fisher stock heads into the open after a 1.75 percent drop - AD HOC NEWS
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MarketWatch
If You Invested $1000 In Thermo Fisher Scientific Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Thermo Fisher (NYSE:TMO): Can New Products Justify Its Valuation? - Kalkine Media
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
IVD Raw Material Market Report Now Available — Forecasts Market Growth from $21.5B (2026) to $31.1B by 2031, Profiling Merck KGaA, Thermo Fisher, Bio-Techne, Fapon Biotech, and 21 Other Key Players - uk.finance.yahoo.com
Thermo Fisher stock heads into the open after a modest recent gain - ad-hoc-news.de
Thermo Fisher stock holds steady after solid mid-year results - AD HOC NEWS
Thermo Fisher Scientific (NYSE:TMO): Can Demand Outweigh Macro Risks? - Kalkine Media
Is Thermo Fisher Scientific (NYSE:TMO) Ready for Another Breakout? - Kalkine Media
Thermo Fisher Scientific Inc. (TMO) Stock Analysis: A Leading Healthcare Giant with Strong Revenue Growth Prospects - DirectorsTalk Interviews
Thermo Fisher Scientific (NYSE:TMO) Shows Strong Technical Breakout Setup - ChartMill
Thermo Fisher CEO: ‘Society broadly embraces the breakthroughs’ - Financial Times
Thermo Fisher stock trades near consensus target as guidance supports outlook - AD HOC NEWS
How Thermo Fisher’s New Workflow-Focused Lab Instruments At Thermo Fisher Scientific (TMO) Has Changed Its Investment Story - webull.com
Should You Continue to Hold TMO Stock in Your Portfolio? - TradingView
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Baird Adjusts Price Target on Thermo Fisher Scientific to $686 From $652, Keeps Outperform Rating - marketscreener.com
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch
Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis - Business Wire
Thermo Fisher (NYSE: TMO) insider uses stock to cover taxes instead of selling on market - Stock Titan
Thermo Fisher (NYSE: TMO) CAO has 49.899 shares withheld to cover tax or exercise costs - Stock Titan
Thermo Fisher Scientific (NYSE: TMO) CEO uses shares to cover taxes and discloses trust holdings - Stock Titan
Thermo Fisher (NYSE: TMO) HR chief uses 394 shares to cover exercise price or tax liability - Stock Titan
Equity award costs paid in stock at Thermo Fisher (TMO) - Stock Titan
Thermo Fisher Scientific to Present at the Morgan Stanley 24 - Business Wire
Thermo Fisher Scientific (TMO) Unveils New Tools For Electron Microscopy And Isotope Analysis - Yahoo Finance
Thermo Fisher (NYSE: TMO) executive to sell 4,133 shares - Stock Titan
Is Thermo Fisher Scientific Stock Outperforming the Nasdaq? - Barchart.com
Thermo Fisher Scientific Inc. (TMO): Investor Outlook with a 1.49% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Thermo Fisher Scientific Inc. stock falls Friday, underperforms market - MarketWatch
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research - BioSpace
Thermo Fisher (NYSE: TMO) CEO exercises options, sells 275 shares - Stock Titan
Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers for Isotope Ratio Analysis, Enabling More Labs to Decode the Story Behind a Sample - Yahoo Finance
Thermo Fisher (NYSE: TMO) CEO exercises options, sells 20K shares - Stock Titan
Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q2 Strength And Analyst Revisions - Yahoo Finance
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):